HUTCHMED (China) Limited (HCM) RNS Announcements

Add to Alert list
Date Time Source Announcement
30 Jun 2021 10:02 AM
RNS
Holdings in Company
30 Jun 2021 10:01 AM
RNS
Total Voting Rights
30 Jun 2021 10:00 AM
RNS
Closing of Global Offering and Hong Kong Listing
29 Jun 2021 07:00 AM
RNS
Blocklisting Six Monthly Return
23 Jun 2021 03:21 PM
RNS
HUTCHMED Announces Pricing of Global Offering
22 Jun 2021 06:22 PM
RNS
Savolitinib approved in China for lung cancer
18 Jun 2021 04:05 PM
RNS
HUTCHMED Announces NMPA Approval of Surufatinib
18 Jun 2021 07:01 AM
RNS
HUTCHMED Launches Hong Kong IPO
18 Jun 2021 07:00 AM
RNS
Disclosure Update
20 May 2021 07:00 AM
RNS
Clinical Data to be Presented at ASCO21
17 May 2021 07:00 AM
RNS
HUTCHMED to Host Company Update
07 May 2021 12:00 PM
RNS
HUTCHMED to Attend Upcoming Investor Conferences
04 May 2021 08:00 AM
RNS
Change of Company Name
04 May 2021 07:00 AM
RNS
Surufatinib FDA Rolling NDA Submission Completed
30 Apr 2021 04:41 PM
RNS
Second Price Monitoring Extn
30 Apr 2021 04:35 PM
RNS
Price Monitoring Extension
29 Apr 2021 07:00 AM
RNS
Phase II Registration Study of HMPL-689 Initiated
28 Apr 2021 02:20 PM
RNS
Result of AGM
23 Apr 2021 07:00 AM
RNS
Vesting of awards under Long Term Incentive Plan
14 Apr 2021 10:30 AM
RNS
Notification of Dilution of Voting Rights
08 Apr 2021 08:30 AM
RNS
$100m Investment by Baring Private Equity Asia
31 Mar 2021 07:00 AM
RNS
Total Voting Rights
29 Mar 2021 09:30 AM
RNS
Grant of LTIP Awards and Share Options
29 Mar 2021 07:00 AM
RNS
Initiates International Phase I Trials of HMPL-306
26 Mar 2021 07:00 AM
RNS
Annual Financial Report
24 Mar 2021 01:30 PM
RNS
Agreement to Divest Non-Core OTC Joint Venture
24 Mar 2021 07:00 AM
RNS
Phase Ib/II Trial of Surufatinib with Tislelizumab
10 Mar 2021 07:00 AM
RNS
Vesting of awards under Long Term Incentive Plan
04 Mar 2021 03:15 PM
RNS
Publication of Form 20-F
04 Mar 2021 12:00 PM
RNS
Final Results, Business Update and Name Change
03 Feb 2021 07:00 AM
RNS
Notice of Results
14 Jan 2021 10:00 AM
RNS
Savolitinib Data to be Presented at Virtual WCLC
11 Jan 2021 07:00 AM
RNS
Chi-Med & Inmagene Announce Strategic Partnership
31 Dec 2020 07:00 AM
RNS
Total Voting Rights
31 Dec 2020 07:00 AM
RNS
Blocklisting Six Monthly Return
30 Dec 2020 12:00 PM
RNS
NMPA approval of Surufatinib in China for ep-NET
29 Dec 2020 07:45 AM
RNS
US NDA Rolling Submission of Surufatinib Initiated
22 Dec 2020 07:00 AM
RNS
Chi-Med to Present at JPM
15 Dec 2020 09:45 AM
RNS
Grant of Share Options under Share Option Scheme
30 Nov 2020 07:00 AM
RNS
Total Voting Rights
27 Nov 2020 07:00 AM
RNS
Notification of Dilution of Voting Rights
17 Nov 2020 07:00 AM
RNS
US$100m Equity Investment by CPP Investments
05 Nov 2020 09:00 AM
RNS
Chi-Med to Present HMPL-689 Clinical Data at ASH
30 Oct 2020 12:00 PM
RNS
Chi-Med to Attend Upcoming Conferences
30 Oct 2020 07:00 AM
RNS
Total Voting Rights
30 Sep 2020 07:00 AM
RNS
Total Voting Rights
21 Sep 2020 07:00 AM
RNS
Surufatinib Data at ESMO and in Lancet Oncology
17 Sep 2020 11:45 AM
RNS
Second Chinese NDA Acceptance for Surufatinib
04 Sep 2020 07:00 AM
RNS
Chi-Med Initiates Global Phase III Trial
03 Sep 2020 07:00 AM
RNS
Chi-Med Initiates a Phase II Trial

Hutchmed China  Limited develops, manufactures, and sells pharmaceutical products. The Company offers drugs for oncology and autoimmune diseases treatment. HUTCHMED (China) is headquartered in Hong Kong and markets its products worldwide.

It was founded in 2000 and listed in London in 2018 under the ticker HCM. 

UK 100